Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 3 Urinary Bladder Neoplasms 1 Ureteral Neoplasms 1 Pancreatic Neoplasms 1 Neoplasms by Site 1 Neoplasm Metastasis 1 Liver Neoplasms 1 Liver Diseases 1 Hemangiosarcoma 1 Digestive System Neoplasms 1 Carcinoma, Transitional Cell 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma, Hepatocellular 1

Interventions

Paclitaxel 6 Doxorubicin 6 Gemcitabine 4 Bevacizumab 4 pembrolizumab 3 pazopanib 3 durvalumab 3 Sorafenib 3 Docetaxel 3 trebananib 2 spartalizumab 2 cemiplimab 2 brostallicin 2 Propranolol 2 Nivolumab 2 Magnetic Resonance Spectroscopy 2 Ipilimumab 2 Imatinib Mesylate 2 Ifosfamide 2 Carboplatin 2 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 2 zanidatamab 1 veliparib 1 tucatinib 1 trilaciclib 1 tremelimumab 1 trastuzumab duocarmazine 1 temsirolimus 1 talimogene laherparepvec 1 talazoparib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Hemangiosarcoma × genexol-PM × Clear all

NCT03512834 2018-07-11

ASAP

Dong-A University Hospital

Phase 2 Unknown

Hemangiosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡